Join China Hi-Tech Fair 2024, Where Innovation Meets Global Opportunity

22.7.2024 03:30:00 EEST | Business Wire | Press release

The 26^th China Hi-Tech Fair (CHTF) is set to take place on November 14-16, 2024, at the Shenzhen World Exhibition & Convention Center. As China’s leading and most influential technology event, CHTF offers an unparalleled platform for tech companies worldwide to showcase their latest innovations, engage with industry leaders, and expand their market reach.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721948434/en/

Embrace Innovation, Drive Growth

Over the past 25 years, CHTF has established itself as a beacon for technological advancement and international cooperation. With this year’s theme “Technology Leads Development, Industry Integrates Fusion,” the fair underscores the critical role of innovation in driving industrial integration and economic growth.

Concurrent Events

Alongside the exhibition, a lineup of over 150 concurrent events will explore groundbreaking ideas and foster collaboration. These include:

The 7th China Green Economy Summit and Chinese Cities Investment Attracting Conference
Innovative Biological Drugs and Cell Quality Progress Forum
Molecular Diagnosis and Companion Diagnosis Summit Forum
Antibody Drugs and New Drug R&D Innovation Forum
Gene Sequencing Application Development Forum
Southern University of Science and Technology Forum
International Cross-domain Cooperation and Collaborative Development of Cross-border E-commerce Forum
China Silicon Photonics Industry Forum
AI Terminal, Intelligent Positioning System New Product Launch
2024 New Quality Productivity Summit

Unparalleled Market Access and Networking Opportunities:

Unmatched Exposure: To attract over 500,000 attendees, including 150 domestic and international delegations from 105 countries and regions.
Influential Audience: To engage with more than 10,000 technological projects and 5,000 exhibitors, including 800+ listed companies and 400+ CEOs and entrepreneurs from multinational corporations.
Media Reach: To gain extensive media coverage from over 1,500 journalists representing 200 domestic and overseas media organizations, ensuring global visibility.
Industry Leaders: To network with prominent figures such as Nobel Prize winners and top industry scholars, enhancing your brand’s credibility and influence.

CHTF is where global innovation converges, serving as a gateway to China’s booming tech market. It offers invaluable insights into market trends and fosters partnerships on a global scale, making it an unmissable event for anyone involved in the technology sector.

To register as an exhibitor, please visit here.

To register as a visitor, please visit here.

For more information, please visit www.chtf.com/english/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240721948434/en/

Contacts

Media Cooperation
Ms. Ocean An
ah@zhenweiexpo.com

Booth Booking
Ms. Donna Hau
hjn@zhenweiexpo.com

Visitor Enquiry
Ms. Sarah Wang
sarah@zhenweiexpo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom